Hearts & Minds Blog

Bringing My Life’s Work to Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

As February comes to a close, we reflect on the importance of recognizing American Heart Month, a time dedicated to… more

Cost-Effective Innovation

Tim Mayleben

President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with… more

Reflections One Year Post-IPO

Tim Mayleben

President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million… more

Posted In: Company News

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than… more

Providing an Alternative for LDL-C Lowering

Tim Mayleben

President and Chief Executive Officer

Brian Orelli’s recent article in BioWorld Insight, “Avoiding the PCSK9 frenzy with alternative drug targets,” highlights how the focus and… more